Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organoid-guided personalized treatment vs physician's choice in refractory breast cancer
NCT06268652Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-free survival at 48 months. Started Jan 2024; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06268652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268652.